A receptor study demonstrated substantial pharmacological diversity among prescription and designer benzodiazepines, without directly ranking their clinical toxicity.
Investigators tested forty-two designer and eleven prescription benzodiazepines in an alpha1–beta2–gamma2 GABAA assay and examined flumazenil interactions. Most enhanced GABA responses. Tested metabolites were active, while two substituted diazepam compounds showed negative modulation that was not antagonized by flumazenil. Potency and maximal activity varied substantially.
The assay used one receptor configuration and controlled concentrations. Human exposure also depends on absorption, metabolism, protein binding, distribution and other receptor subtypes. Laboratory potency ratios cannot be read as equivalent tablet doses, impairment ratios or fatal-concentration thresholds. Active metabolites may have very different abundance in actual patients.
For novel-drug testimony, specify whether a claim concerns binding, functional modulation, clinical effect or exposure. Structural similarity does not guarantee identical behavior. This source supports testing new compounds rather than assuming interchangeability, and it cannot independently establish how much a detected designer benzodiazepine contributed to one death.
Source reviewed: In vitro aminobutyric acid A GABAA receptor activity and binding interactions at the 2 interface of (PMC13068902). Forensic applications above are interpretive analysis of the supplied paper.
Related reading: A Benzodiazepine-Receptor PET Tracer Had Binding Components Hidden by the Total Signal.